After a 92% share price crash, is this a bargain basement growth stock?

This Fool’s wondering if there’s a golden opportunity in Novocure (NASDAQ:NVCR) now the once-high-flying growth stock has fallen off a cliff.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Bronze bull and bear figurines

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a few years since I last cast an eye over Novocure (NASDAQ: NVCR). So I was surprised to see how hard this growth stock (once a Nasdaq darling) has fallen. From a high of $221 in the summer of 2021, it’s now trading for just $17.

That’s a wealth-shredding 92% drop over three years!

Is this fallen star now a bargain hiding in plain sight? Or is this one to avoid? Let’s dig into the details.

Should you invest £1,000 in Nike right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Nike made the list?

See the 6 stocks

Created with Highcharts 11.4.3NovoCure PriceZoom1M3M6MYTD1Y5Y10YALL15 Aug 201915 Aug 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

What does it do?

Novocure is a medical device company specialising in a unique cancer treatment called Tumour Treating Fields (TTFields). This non-invasive therapy uses electric fields to disrupt cancer cell division, slowing the spread of tumours.

The wearable device primarily targets glioblastoma, a particularly aggressive type of brain cancer. The patches on the scalp deliver electric fields and are connected to a portable device, often carried like a backpack, allowing continuous cancer treatment while maintaining mobility.

At the end of June, there were 3,963 active patients using TTFields therapy, an 11% increase from the previous year. 

Mixed results

I was first attracted to the share a few years ago when I heard the firm’s proprietary technology being called the “fourth modality of cancer treatment” (along with surgery, chemotherapy, and radiation).

The hope was that its technology would become a standard treatment for several types of cancer. However, while Novocure has expanded its research to include non-small cell lung cancer, pancreatic cancer, and ovarian cancer, it’s had mixed results so far.

Last year, its phase 3 trial of TTFields in patients with a type of ovarian cancer failed to meet its primary endpoint. On the plus side, it announced earlier this year that its Phase 3 METIS trial, involving patients with lung cancer that had spread to the brain, did meet its primary endpoint. Final results are pending.

Looking forward, a lot will hinge on data due later this year from its phase 3 PANOVA-3 clinical trial in advanced pancreatic cancer. If that is successful, it could open up a significant growth opportunity and be a big catalyst for the stock.

Of course, there’s also a risk these results could disappoint and heap further pressure on the share price.

Sluggish growth and zero profits

The company’s revenue growth has stalled in recent years. And while brokers see a bit of growth in the next couple of years, it isn’t anything to get overly excited about.

Revenue
2022$538m
2023$509m
2024$580m (forecast)
2025$616m (forecast)

Meanwhile, the firm reported a net loss of $207m last year. And Wall Street has a $150m loss pencilled in for each of the next two years.

That said, the company isn’t in any danger of going under. At the end of June, its cash and short-term investments totalled $951m. But the losses do add risk to the investment case here.

My move

Novocure appears close to expanding its TTFields technology to several cancer types and this could significantly increase its addressable market.

Plus, the stock is trading on a price-to-sales (P/S) ratio of around 3.5. Not obvious bargain territory perhaps, but a lot cheaper than 2021 when the P/S multiple was 14.5.

This share could be set for a big turnaround at some point. So I’m going to keep it on my watchlist while I wait for the company’s upcoming clinical trial results.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Nike right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Nike made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

artificial intelligence investing algorithms
Investing Articles

Up 272% in just a year, is Palantir stock just getting started?

This writer recognises that Palantir has grown its business very well -- but does the stock price offer him an…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Up 50%? The Aston Martin share price forecast is mind-blowing! 

If analysts are right, the Aston Aston Martin share price could absolutely rocket in the year ahead. Harvey Jones says…

Read more »

Investing Articles

As the S&P 500 drops, here are 2 Stocks and Shares ISA holdings I’m watching

Our writer has different views on how President Trump's tariffs might affect these two US holdings in his Stocks and…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10,000 invested in Tesla stock at Christmas is now worth…

Tesla stock has been one of best-performing investments of the past decade. But things haven't gone to plan for investors…

Read more »

Investing Articles

Up 279% in 5 years, could Meta stock keep soaring?

Meta stock has more than tripled in five years. This writer sees lots to like about the business but also…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

25% total return in a year? Is now the perfect time to buy BP shares?

BP shares are on the front line of today's global economic and political uncertainty but analysts think they can still…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

With Cash ISA changes coming, could now be the time to consider buying shares?

Changes to the Cash ISA could lead to greater investment in the stock market. This could be a good thing…

Read more »

Investing Articles

These FTSE 100 dividend shares just got cheaper, thanks to President Trump!

Investors buying dividend shares can lock in bigger long-term yields when share prices take a tumble. These two just did…

Read more »